Drug Profile
ACH 24
Alternative Names: ACH24Latest Information Update: 04 Dec 2017
Price :
$50
*
At a glance
- Originator Ache Laboratories
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Vitiligo
Most Recent Events
- 04 Dec 2017 ACH 24 is still at phase I/II development stage for Vitiligo in Brazil (Ache Laboratories pipeline, December 2017)
- 15 Mar 2016 Brazilian Health Surveillance Agency (ANVISA) requests Ache Laboratories to conduct a phase I trial of ACH 24
- 15 Mar 2016 Ache Laboratories withdraws a phase III trial for Vitiligo in Brazil (NCT01419964)